Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-icap No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Koji Murota) as unlimited liability partner, has made an additional investment in Sias Corporation ("Sias"), a venture company that utilizes the results of Kyoto University's research. ("Sias") (Head office: Sakyo-ku, Kyoto; Representative Director: Yasumichi Hitoshi), a venture company that utilizes research results from Kyoto University.

Outline of this investment
Sias is a regenerative medicine venture that aims to regenerate T cells using human iPS cells generated from patients' own cytotoxic T cells (killer T cells, CTL) and to commercialize T cell therapy for cancer and infectious diseases. CTLs infiltrated into a patient's tumor tissue or peripheral blood have the ability to recognize and specifically injure cancer cells, and are expected to have anti-tumor effects when cultured, proliferated, and transplanted. However, CTLs are difficult to culture and proliferate in vitro, and their cytotoxic activity declines due to exhaustion of the CTLs themselves. By initializing CTLs into iPS cells, the exhaustion of CTLs is removed, and CTLs with cytotoxic activity can be differentiated and induced again, and can be proliferated in large quantities. Sias aims to realize the world's first immunotherapy using autologous regenerated T cells with this technology.

Sias has entered into a joint research agreement with the Kaneko Laboratory (Associate Professor Arata Kaneko) of the Center for iPS Cell Research and Application (CiRA), Kyoto University, to apply regenerative T cells to autologous therapy and to develop next-generation technologies. Sias has been working to enhance its patent portfolio by securing exclusive non-exclusive licenses for a group of patents from Kyoto University related to technology for inducing differentiation into functional T cells and a group of patents from OncoTherapy Science, Inc. (Head Office: Kawasaki, Kanagawa, Japan; President: Kyoko Fujitani) for a peptide vaccine. In addition, we are now steadily preparing for the early commencement of pre-clinical and clinical trials.

Kyoto iCAP decided to make this investment in recognition of the challenge and social significance of Sias' efforts to deliver regenerative T-cell therapy, which could become an important technology for advanced cancer immunotherapy using Kyoto University's iPS cell technology, to patients as soon as possible. Kyoto iCAP is a joint venture between Chushin Venture Capital (President: Sachiko Hirabayashi) and Future Venture Capital (Head office: Nakagyo-ku, Kyoto; President: Naoto Matsumoto). (headquartered in Nakagyo-ku, Kyoto City, Kyoto; President: Naoto Matsumoto) as the general partner, and Kyoshin Innovation C Investment Limited Partnership, with Future Venture Capital Co.

Outline of Sias Corporation

Establishment	August 24, 2015
Business	Development of therapies for cancer and other diseases using regenerated T cells
Head Office Location	Sakyo-ku, Kyoto
President & CEO	etc.